<DOC>
	<DOCNO>NCT00743340</DOCNO>
	<brief_summary>The purpose study provide current FTC-203 study participant South Africa continue access study drug , emtricitabine , follow completion FTC-203 study . Individuals participate rollover protocol receive emtricitabine , long continue meet specific virologic criterion withdraw study , experience toxicity necessitates permanent discontinuation emtricitabine , emtricitabine approve country residence .</brief_summary>
	<brief_title>Rollover Study Protocol Pediatric Patients South Africa Continued Access Emtricitabine</brief_title>
	<detailed_description>In addition access emtricitabine , study collect long-term safety information participant receive emtricitabine combination antiretroviral agent . Data collection rollover protocol safety purpose limit report adverse event ( AEs ) ( 1 ) meet criterion serious adverse event ( SAE ) , ( 2 ) result permanent discontinuation study drug , emtricitabine , and/or ( 3 ) associate skin discoloration ( hyperpigmentation ) .</detailed_description>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Key Complete previously complete least Week 96 Visit ( i.e. , 96 week study ) FTC203 study . Complete EndofStudy Visit procedures FTC203 study . Either ( ) plasma HIV1 RNA viral load â‰¤ 400 copies/mL EndofStudy Visit FTC203 study , ( b ) subject 's plasma HIV1 RNA viral load EndofStudy Visit FTC203 study &gt; 400 copies/mL , viral load &lt; 1.0 log10 nadir record Week 8 FTC203 study reliable genotypic evidence show lack resistance emtricitabine . A parent legal guardian provide write informed consent subject participate rollover protocol . As applicable , base subject 's age normal institution practice , subject additionally provide write informed consent assent participate rollover protocol . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>pediatrics</keyword>
	<keyword>pediatric patient</keyword>
</DOC>